 |
|
The Value of Specifying Brand-name Antiepileptic Drugs
Yu-tze Ng, MD, FRACP
Arch Neurol. 2009;66(11):1415-1416.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The patent lives of most of the newer-generation antiepileptic drugs (AEDs) have either expired or come close to expiration. This is despite occasional attempts by the pharmaceutical industry to extend patent lives by creating a variation of an existing compound/AED, often in the form of an extended-release version, eg, Lamictal XR and Keppra XR. Inevitably the question of generic substitution of our patients' AEDs arises, usually prompted by the paying insurance companies whose main interest is the bottom line, though it is not infrequently prompted by the (self-paying) patients or their families. This brief commentary will not attempt to be a comprehensive review of this topic, which have already been written.1-4
There is a saying in the management of epilepsy that most of us who treat such patients are well aware of: "If it ain't broke, don't fix it." That simply means of course that if . . . [Full Text of this Article] AUTHOR INFORMATION
Author Affiliation: Division of Pediatric Neurology, Barrow Neurological Institute/St Joseph's Medical Health Center, Phoenix, Arizona.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Lorie D. Hamiwka
Arch Neurol. 2009;66(11):1417-1418.
EXTRACT
| FULL TEXT
The Cost of Gullibility
E. S. Roach
Arch Neurol. 2009;66(11):1418-1420.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Cost of Gullibility
Roach
Arch Neurol 2009;66:1418-1420.
FULL TEXT
|
